Replimune gets a second chance, while Sarclisa could go subcutaneous.
ApexOnco Front Page
Recent articles
After a delay, the Alpha-3 study faces an April futility analysis.
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
But there are no efficacy data, and the mechanism has a mountain to climb.
CRB-601 and PF-06940434 fall by the wayside.
BPI-572270 enters clinical trials.
The company has ditched a trial of drebuxelimab plus ivonescimab.
